Advertisement covers the 17th Conference on Retroviruses and
Opportunistic Infections  Shorter Duration of TB-Prevention
Therapy Including Ethambutol May Be Effective, Study Suggests  A
Discussion With Soumya Swaminathan, M.D.  March 3, 2010
Multimedia Toolbox  Listen to Audio (8 min.)   Below is the
transcript of a press conference held at CROI 2010 on Feb. 18,
featuring Soumya Swaminathan, M.D., of the Tuberculosis Research
Center in Chennai, India. She discussed the outcome of a trial
comparing a six-month course of tuberculosis (TB) prevention
therapy to a three-year course among people with HIV.  Soumya
Swaminathan: I presented data that was done at the Tuberculosis
Research Center, which is in Chennai in South India. This was a
randomized clinical trial to look at the efficacy of two
different regimens to prevent tuberculosis [TB] in HIV-infected
persons.1 TB is one of the biggest killers of HIV-infected
people in India and other TB-endemic countries, so preventive
therapy for TB would go a long way in